ASCENDIS HEALTH LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8 ZAR | 0.00% |
|
0.00% | +2.56% |
| 29/03 | Ascendis Health Seeks Acquisitions | CI |
| 28/03 | Ascendis Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 1.56B 82.78M 6.9B | Sales 2023 | 1.54B 81.5M 6.8B | Capitalization | 412M 21.87M 1.82B |
|---|---|---|---|---|---|
| Net income 2022 | 449M 23.83M 1.99B | Net income 2023 | 75M 3.98M 332M | EV / Sales 2022 | 0.48 x |
| Net Debt 2022 | 424M 22.52M 1.88B | Net cash position 2023 | 55.12M 2.93M 244M | EV / Sales 2023 | 0.23 x |
| P/E ratio 2022 |
0.73
x | P/E ratio 2023 |
5.31
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.48% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -1.23% | ||
| 1 month | -1.23% | ||
| 3 months | +1.27% | ||
| 6 months | +17.65% | ||
| Current year | +2.56% |
1 week
0.78
0.80
1 month
0.700.81
Current year
0.700.83
1 year
0.590.83
3 years
0.451.30
5 years
0.295.80
10 years
0.2929.39
| Managers | Title | Age | Since |
|---|---|---|---|
Carl Neethling
CEO | Chief Executive Officer | - | 13/22/13 |
Joseph Fine
SEC | Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Theunis de Bruyn
BRD | Director/Board Member | 56 | 19/22/19 |
Bharti Harie
CHM | Chairman | 53 | 13/22/13 |
Carl Neethling
CEO | Chief Executive Officer | - | 13/22/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.8 | 0.00% | 0 |
| 25/24/25 | 0.8 | +2.56% | 30,100 |
| 24/24/24 | 0.78 | -2.50% | 66,888 |
| 23/24/23 | 0.8 | 0.00% | 66,452 |
| 22/24/22 | 0.8 | 0.00% | 26,990 |
End-of-day quote Johannesburg S.E., April 26, 2024
More quotes
Ascendis Health Limited specializes in developing, manufacturing and marketing care and health products. Net sales break down by family of products as follows:
- pharmaceutical products (61.3%): primarily prescription drugs. The group also provides medical devices used in the radiology and surgery fields;
- consumer products (31%): OTC medicines, vitamins and minerals, homeopathic products, ayurvedic products, sports nutrition products, functional foods, etc.;
- care products for plants and animals (7.7%).
Net sales are distributed geographically as follows: South Africa (71.3%), Cyprus (16%) and Romania (12.7%).
Sector
Pharmaceuticals
Calendar
26/09/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.56% | 26.6M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ASC Stock
